Inhaled Nitric Oxide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The inhaled nitric oxide market size is expected to grow from USD 1.02 billion in 2025 to USD 1.10 billion in 2026 and is forecast to reach USD 1.65 billion by 2031 at 8.29% CAGR over 2026-2031. This report is Segmented by Product Type (Inhaled Nitric Oxide Gas, Nitric Oxide Generators & Delivery Systems, and More), Application (Neonatal Respiratory Treatment, Asthma and COPD, and More), End-User (Tertiary Hospitals & NICUs, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Inhaled Nitric Oxide Market Trends and Insights

Escalating Burden of Neonatal and Acute Pulmonary Disorders Worldwide

Persistent pulmonary hypertension of the newborn affects 1.5-2 per 1,000 term and late-preterm births, underpinning steady NICU demand. Countries with high birth rates and improving intensive-care capacity, notably India and China, are scaling nitric-oxide protocols in neonatal guidelines. In parallel, ARDS now represents roughly 10% of ICU admissions worldwide, enlarging the adult addressable pool. During the COVID-19 surge, multi-center studies reported improvements in oxygenation metrics in up to 60% of severe cases when inhaled NO was added to ventilation strategies, cementing off-label traction that continues in 2025.

Technological Advancements in Cylinder-Free NO Generation and Dosing Equipment

Generator-based systems eliminate high-pressure cylinders, slashing storage hazards and transport costs. Beyond Air’s FDA-cleared LungFit PH produces NO on demand from ambient air at bedside concentrations up to 400 ppm, far above the 80 ppm ceiling of legacy units, and integrates with ventilators through proprietary dosing software. Hospitals benefit from simplified logistics, reduced greenhouse-gas emissions linked to cylinder deliveries, and the ability to deploy therapy in operating rooms without respiratory-therapy set-up delays.

High Capital and Operational Costs of NO Delivery Systems

Legacy cylinder-based platforms require upfront outlays of USD 50,000-100,000 plus recurring consumable expenses near USD 3,000 per patient-day in the United States. Budget-constrained hospitals ration use to the most critical neonates and adults, limiting penetration across lower-tier centers. Even in developed markets, pharmacy committees enforce utilization protocols to curb spending, prompting interest in generator models that promise cost savings over device lifecycles.

Other drivers and restraints analyzed in the detailed report include:

• Favorable Orphan-Drug Reimbursement Policies in High-Income Markets
• Expanding Critical-Care Infrastructure Across Emerging Economies
• Stringent Safety Regulations for Storage and Transport of Toxic Gases

Segment Analysis

The inhaled nitric oxide gas segment maintained a 71.80% revenue position in 2025. Familiarity, national formularies, and integrated cylinder supply chainshave entrenched the incumbent approach in NICUs and adult ICUs. Yet generator-based platforms are forecast to expand at 10.18% CAGR to 2031 as hospitals blend sustainability mandates with business-case savings. Cylinder-free units eliminate the need for costly bulk-gas contracts and lower carbon-emission footprints tied to transport. Device makers now bundle ventilator-compatible cartridges, software-driven dosing, and cloud diagnostics, reducing alarm fatigue and downtime. Integrated ventilator modules, deployed through partnerships between industrial-gas firms and ventilator manufacturers, streamline therapy initiation during intra-hospital transport. Accessories and consumables remain a predictable profit center, with filter and connector kits replaced on rigid preventive-maintenance cycles.

Competition now pivots on intellectual-property firewalls around plasma-ionization technology, smart-sensor feedback, and antimicrobial tubing. Market entrants tout higher maximum‐dose ceilings that allow experimental regimens in refractory hypoxemia and oncology. Generators capable of delivering 400-ppm doses at bedside encourage protocol expansion beyond conventional 80-ppm limits. These advances are reshaping procurement criteria, with purchasing teams ranking footprint, connectivity, and multiyear total-cost-of-ownership ahead of traditional per-hour pricing.

Complete Report Scope:

• By Product Type
  • Inhaled Nitric Oxide Gas
  • Nitric Oxide Generators & Delivery Systems
  • Integrated Ventilator Modules
  • Accessories & Consumables
• By Application
  • Neonatal Respiratory Treatment
  • Asthma and COPD
  • Acute Respiratory Distress Syndrome
  • Malaria Treatment
  • Tuberculosis Treatment
  • Other Applications
• By End-User
  • Tertiary Hospitals & NICUs
  • Specialty Pulmonary Clinics
  • Ambulatory Surgical Centres
  • Home-Care Settings
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America remained the epicenter of the inhaled nitric oxide market in 2025, generating 48.60% of global revenue. Roughly 25,000 U.S. neonates receive therapy each year across more than 800 NICUs. Medicare, Medicaid, and most private insurers reimburse USD 3,000-plus daily therapy costs, protecting provider margins. Canada shows rising adoption in provincial tertiary centers, while Mexico is incorporating nitric oxide into updated neonatal hypoxic-failure guidelines amid hospital-modernization funding. Regional growth is underpinned by early-stage home-therapy trials enrolling pulmonary-hypertension patients discharged with portable generators.

Asia Pacific is the fastest-growing territory, with inhaled nitric oxide market revenues primed for a 9.10% CAGR. China’s Healthy China 2030 blueprint prioritizes neonatal-mortality reduction, spurring procurement of advanced respiratory modalities in top-tier urban hospitals. The National Health Commission green-lighted reimbursements for persistent pulmonary-hypertension protocols that include nitric oxide, boosting penetration from 65 major facilities in 2023 to more than 140 in 2025. Japanese hospitals report the highest per capita utilization, reflecting universal coverage and mature NICU networks. India’s public-private NICU expansion and large annual birth cohort create long-term upside, although gaps in rural infrastructure constrain near-term uptake. Europe generated about 30.40% of 2025 revenue, led by Germany, France, and the United Kingdom. Reimbursement is contingent on cost-utility analysis, so hospitals evaluate total oxygenator days avoided and ECMO deferrals when justifying purchases of next-generation devices. Cylinder-free generators resonate with sustainability mandates embedded in European Green Deal agendas. Eastern-European adoption is accelerating through EU-funded hospital-upgrade programs. The Middle East counts fewer total treatments but high revenue per site as Gulf Cooperation Council hospitals procure premium generator-ventilator bundles for new-build NICUs. African uptake remains nascent except in South-Africa-based academic centers focused on neonatal-asphyxia reduction.

List of Companies Covered in this Report:

• Mallinckrodt Pharmaceuticals plc
• Linde plc
• Air Liquide
• VERO Biotech LLC
• Beyond Air
• Bellerophon Therapeutics Inc.
• Praxair Distribution
• BOC Healthcare
• Airgas Inc.
• Matheson Tri-Gas
• Nu-Med Plus
• Hamilton Medical
• GE Healthcare
• Philips Respironics
• Perma Pure
• Halma
• OxGen Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support